US EditionTrump executive order backs change to Medicare negotiation pushed by drug industry
- President Donald Trump signed a multi-part executive order on April 15, 2025, aiming to lower Medicare prescription drug prices in the United States.
- The order expands efforts initiated during the Biden administration's Medicare Drug Price Negotiation Program by aiming to align Medicare payment rates and explore hospital price matching strategies to help lower prescription drug costs.
- It also includes provisions for lowering insulin prices to as little as 3 cents for low-income or uninsured patients, supports drug importation programs, and requires health centers to pass discounts on insulin and epinephrine to patients.
- The initiatives aim to reduce patient drug expenses by as much as 60%, with projected Medicare savings of $6 billion and a $1.5 billion decrease in out-of-pocket costs for seniors, based on estimates from the White House.
- The administration acknowledged it must collaborate with Congress and warned that tariffs on pharmaceutical imports might raise prices, while critics said payment changes could harm local hospitals relying on high reimbursements.
153 Articles
153 Articles
President Trump Signs EO to Lower Cost of Wide Range of Prescription Medications
President Donald Trump has signed a sweeping executive order to bring down drug prices in America, taking aim at prescription imports, Medicare overcharges, and middlemen in the supply chain. The order could make common medications—including insulin—dramatically cheaper for many Americans. Key Facts: Lowering Cost of Prescriptions Through Executive Action Trump signed the executive order on April 15 to reduce prescription drug costs through var…
Trump's Price Transparency Rule 'Cements' His Legacy of Lowering Healthcare Costs
President Donald Trump's executive order to enforce healthcare price transparency has been hailed as transformative in lowering costs and "cements Trump's legacy" as a leader in healthcare reform.
Drug Pricing Executive Order Boosts Pharmaceutical Industry’s Goals
On Tuesday, President Trump issued an executive order on prescription drug pricing that supports key drug industry efforts to weaken the Inflation Reduction Act’s (IRA) Medicare negotiation program, putting Medicare and beneficiary savings at risk. Since the IRA’s passage, drugmakers have been seeking ways to dilute or sidestep the negotiations, including by bolstering exemptions for certain medications. Since the IRA’s passage, drugmakers have …
Mark Cuban backs Trump's health care executive order on prescription drugs
Billionaire entrepreneur Mark Cuban on Wednesday expressed support for President Donald Trump's executive order on healthcare and drug pricing despite his longstanding opposition to many of the president's policies."Shark Tank" star Mark Cuban, who founded pharmaceutical firm Cost Plus Drugs in 2022 as a public benefit corporation to lower prices for generic drugs, said that the Trump administration executive order released earlier in the week c…
President Trump Signs EO to Lower Drug Prices, Boost Innovation - Americans for Tax Reform
On April 15th, President Trump signed an executive order aimed at lowering prescription drug prices. This EO contains several provisions that will protect medical innovation and reduce the cost of medicine for Americans. Notably, these provisions include fixing the Inflation Reduction Act’s pill penalty, accelerating the approval of generics/biosimilars, and scrutinizing government spending on healthcare. President Trump should be applauded for …
Coverage Details
Bias Distribution
- 55% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
